Spruce Biosciences, Inc. (SPRB)
59.00
-1.78
(-2.93%)
USD |
NASDAQ |
Aug 31, 16:00
59.00
0.00 (0.00%)
After-Hours: 18:26
Spruce Biosciences Cash from Investing (Quarterly) : -0.135M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.135M |
| March 31, 2026 | -0.01M |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 9.30M |
| September 30, 2023 | 13.99M |
| June 30, 2023 | 22.00M |
| March 31, 2023 | 10.48M |
| Date | Value |
|---|---|
| December 31, 2022 | 14.57M |
| September 30, 2022 | -16.89M |
| June 30, 2022 | 33.51M |
| March 31, 2022 | -7.491M |
| December 31, 2021 | -5.983M |
| September 30, 2021 | -12.34M |
| June 30, 2021 | -60.83M |
| March 31, 2021 | -0.019M |
| December 31, 2020 | -0.024M |
| September 30, 2020 | -0.043M |
| June 30, 2020 | -0.007M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | -0.001M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biogen, Inc. | -3.839B |
| PTC Therapeutics, Inc. | -122.56M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.12M |
| Cash from Financing (Quarterly) | 64.47M |
| Free Cash Flow | -42.77M |
| Free Cash Flow Per Share (Quarterly) | -9.154 |
| Free Cash Flow to Equity (Quarterly) | -22.80M |
| Free Cash Flow to Firm (Quarterly) | -21.16M |
| Free Cash Flow Yield | -50.53% |